Uracil-tegafur in early-stage lung cancer [1] (multiple letters)

New England Journal of Medicine

Volumn 351, Issue 7, 2004, Pages 713-714

  Altundag, Ozden ^a   Altundag, Kadri ^a   Gunduz, Mehmet ^b   Graziano, Francesco ^c   Ichinose, Yukito ^d   Hamajima, Nobuyuki ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b OKAYAMA UNIVERSITY   (Japan)

^c UNIVERSITY OF URBINO   (Italy)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

UFT; 1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; TEGAFUR; URACIL;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG CANCER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; LUNG TUMOR; LYMPH NODE; METHODOLOGY; MULTIVARIATE ANALYSIS; NOTE; PATHOLOGY; MORTALITY; SECOND CANCER; SURVIVAL; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; TEGAFUR; URACIL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4043078432     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200408123510718     Document Type: Letter

References (0)